Boult Wade Tennant
Bulletins » Finally: A referral to the Enlarged Board of Appeal on description amendments

For several years now the European Patent Office (EPO) has insisted upon the adaptation of the description to avoid inconsistencies with amended claims. However, various Boards of Appeal have taken different views on whether there is legal basis in the European Patent Convention (EPC) for such a requirement, and it has caused many headaches for both European and non-European Patent Attorneys. A Board of Appeal has, at last, referred questions on the matter to the Enlarged Board of Appeal (case G1/25) that will hopefully lead to some final clarity on the matter.

Questions referred

The Technical Board of Appeal in case T 697/22 has referred to the Enlarged Board of Appeal the following questions:

  1. If the claims of a European patent are amended during opposition proceedings or opposition-appeal proceedings, and the amendment introduces an inconsistency between the amended claims and the description of the patent, is it necessary, to comply with the requirements of the EPC, to adapt the description to the amended claims so as to remove the inconsistency?
  2. If the first question is answered in the affirmative, which requirement(s) of the EPC necessitate(s) such an adaptation?
  3. Would the answer to questions 1 and 2 be different if the claims of a European patent application are amended during examination proceedings or examination-appeal proceedings, and the amendment introduces an inconsistency between the amended claims and the description of the patent application?

The answers to these questions by the EBA would be very helpful in resolving the issue of whether the EPC requires the description to be amended to conform to amended claims, and what the exact basis for such a requirement is.

Background to the issue of description amendments

The current requirements regarding amendments to the description were introduced to the EPO Guidelines in 2021.The Guidelines require that “any inconsistency between the description and the claims must be avoided if it casts doubt on the subject-matter for which protection is sought, thereby rendering the claim either unclear or unsupported under Art. 84, second sentence, or objectionable under Art. 84, first sentence.” This often involves the applicant being required to delete subject matter in the description which is not covered by the claims or to explicitly state in the description what is and is not covered by the scope of the claims.

There have been a number of decisions of Technical Boards of Appeal which have upheld the requirement in the Guidelines that the description be adapted to be in line with amendments which have been made to the claims and found legal basis in the EPC. However, as noted by the Board in T 697/22, the legal bases upon which these decisions relied varied and there was no consensus on one precise legal basis. Many cases cited Article 84 EPC alone as the legal basis, while others cited Article 84 EPC combined with other legal provisions of the EPC. T 1024/18, wherein the board considered Article 84 EPC to be the legal basis for the description amendment requirement, is itself cited in a number of following decisions where the requirement to amend the description was upheld.

However, there have also been contradicting decisions in recent years. In the recent example of T 56/21 (see our insight here), the Board found that there was no legal basis in the EPC for requiring that the description be adapted to match allowable claims of a more limited subject-matter.

The referral of T 697/22

The referring Board of Appeal in T 697/22 identified these as two clearly diverging lines of case law and, as a result, referred the questions above to the Enlarged Board of Appeal.

In T 697/22, claim 1 of an auxiliary request, which had been found allowable, was narrowed such that it was more limited than the claim as granted. However, the corresponding paragraphs of the description were not amended, and so remained broad. The opponent in T 697/22 objected that this meant that the amended, narrower claim was not supported by the description as required by Article 84 EPC.

The referring Board considered that the question of whether adapting the description to the amended claims to remove inconsistency between the two was necessary to comply with the requirements of the EPC would be decisive to the outcome of the case.

While case T 697/22 relates to opposition-appeal proceedings, the referring Board has also included the third question given that the same divergence of case law exists of examination and examination-appeal proceedings as for opposition and opposition-appeal proceedings. It will be interesting to see if the Enlarged Board of Appeal answers this question, since it is arguably beyond the scope of the opposition proceedings before the referring Board.

The referring Board also highlight that the fundamental character of the questions they have posed is reinforced by the order in G 1/24, which states that the “description and drawings shall always be consulted to interpret the claims when assessing patentability”. They consider that this decision means that the question of discrepancies between the description and amended claims is of even greater significance.

Hopefully, insight from the Enlarged Board of Appeal on these questions will provide much-needed final guidance as to the extent of amendments to the description needed to meet the requirements of the EPC.

Here is a link to the interlocutory decision with the referred questions.

 

 

Relevant sectors
Aerospace
  • Commercial aviation
  • Defence and security
  • Space and satellites
  • Unmanned aerial vehicles
Artificial Intelligence and Machine Learning
Automotive
  • Autonomous vehicles
  • Electric vehicles
  • Engines
Biotechnology
  • Antibody engineering
  • Antibody manufacture and formulation
  • Bioinformatics
  • Biosimilars
  • Drug delivery
  • Gene editing (e.g. CRISPR)
  • Genomic and molecular tools and methods
  • GM crops
  • Immuno-oncology (e.g. checkpoint inhibitors; modified T cells)
  • Next generation sequencing
  • Nucleic acid synthesis
  • Personalised medicine/disease biomarkers
  • Recombinant protein production and purification
  • Stem cell therapies
  • Supplementary protection certificates (SPCs)
  • Synthetic biology
  • Therapeutic antibodies
  • Vaccinology (e.g. viral vectors; mRNA vaccines)
  • Women’s health products
Chemicals
  • Agrochemicals
  • Catalysts
  • Dispersions and colloids
  • Lubricants
  • Polymers and plastics
Communications and Networks
  • Cloud computing
  • Internet of things (IOT)
  • Oceanography, marine
  • Wired and wireless networks
Computing and Software
  • Artificial intelligence and machine learning
  • Bioinformatics
  • Blockchain and distributed ledgers
  • Communications and networks
  • Computer games
  • Data and software security, cryptography and digital rights management (DRM)
  • Data management and storage, databases and data compression
  • Digital assistants, virtual assistants and software agents
  • Fintech and adtech
  • Machine vision
  • Metaverse, virtual reality (VR) and augmented reality (AR)
  • Motor capture
  • Multimedia, audio/video processing and animation
  • Natural language processing
  • Quantum computing
  • Robotic process automation
  • Search engines
  • Signal processing
  • Software applications and systems, mobile applications, user interfaces
Consumer Goods and Retail
  • Anti-counterfeit devices
  • Beauty
  • Fashion
  • Health, fitness and sport
  • Household goods
  • Luxury goods
  • Moda
  • Retail
Electronics and Electrical Devices
  • Computer and IT architecture and system design
  • Medical devices
  • Optics
  • Restaurants and bars
  • Robotics
  • Scientific instruments
  • Semiconductor devices
  • Testing systems, control systems, signal processing
  • Travel and leisure
  • Wearable tech and human interfaces
Energy and Green Technologies
  • Biofuels
  • Clean air
  • Fuel cells and battery technology
  • Renewables and recycling
  • Solar power
  • Water, oil and gas, nuclear, fusion, fission
  • Wind turbines
Food and Beverage
  • Beverages
  • Nutrition
  • Retail
Industrial Manufacturing and Processing
  • Packaging
  • Polymers and plastics
  • Printing tech
  • Additive manufacturing
  • Coatings
  • Construction
Materials
  • Advanced materials
  • Composite materials
  • Metallurgy and alloys
  • Nanotechnology
Medical Devices and Diagnostics
  • Artificial intelligence
  • Devices
  • Diagnostic instruments
  • Digital health
  • Drug delivery
  • Immuno-oncology
  • In vitro diagnostics
  • Medtech
Pharmaceuticals
  • Diagnostics
  • Drug delivery
  • Generic market entry
  • Medicinal chemistry
  • Methods of production and synthesis
  • Personalised medicine/disease biomarkers
  • Pharmaceutical formulations
  • Pharmaceuticalsceutical formulations
  • Polymorphs
  • Small molecule pharmaceuticals
  • Supplementary protection certificates (SPCs)
Trade Marks
  • Consumer goods
  • Cosmetics and perfumery
  • Financial services
  • Mechanical engineering
  • Mechanical products
  • Services
  • Telecommunications
Relevant sectors